JOSEPH DRISCOLL - 22 Dec 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Chief Financial Officer
Signature
/s/ Joseph Driscoll, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
22 Dec 2022
Net transactions value
+$110,000
Form type
4
Filing time
27 Dec 2022, 15:05:02 UTC
Previous filing
16 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $110,000 +250,000 +2000% $0.4400* 262,500 22 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -250,000 -69% $0.000000 110,958 22 Dec 2022 Common Stock 250,000 $0.4400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will be fully vested on 03/18/2023.